Drugs / Human Amniotic Fluid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04319731 | Mar → Jun 2020 | COVID-19 | University of Utah | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT04497389 | Oct 2020 → Aug 2022 | COVID-19 | University of Utah | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Amniotic Fluid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04319731 ↗ |
| Known as | hAF | “Acellular human amniotic fluid (hAF) is an antimicrobial and anti-inflammatory fluid that has been used to treat various pro-inflammatory conditions.” PMID 38066442 ↗ Dec 20231“we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19.” PMID 33482902 ↗ Jan 2021 |
| Route | Intravenous | “10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)” NCT04319731 ↗ |